Pediatric blood & cancerHemophilia AHumansAntibodiesBispecificMonoclonal
Emicizumab in Previously Untreated Patients and Minimally Treated Patients With Hemophilia A: A Comparative Study Between Two International Cohorts.
Sarina Levy-Mendelovich, Tlalit Barhod, Ivan Budnik, Jonathan Lancashire, Jesal Patel, Assaf Arie Barg, Einat Avishai, Rima Dardik, Tami Brutman Barazani, Tami Livnat, Jayashree Motwani, Gili Kenet
Published: 202610.1002/pbc.32118
Abstract
BACKGROUND: Hemophilia A (HA) is a rare bleeding disorder caused by coagulation factor VIII (FVIII) deficiency. Prophylactic FVIII replacement therapy is essential for preventing bleeds, but it carries a risk of inhibitor development, especially in p…
Preview only. Read the full abstract at the source